Related Experiment Videos
Pediatric transplantation: results in solid tumors.
1Division of Hematology/Oncology and Stem Cell Transplantation, Department of Pediatrics, Northwestern University Feinberg School of Medicine, 2300 Children's Plaza, Box #30, Chicago, IL, USA. mkletzel@northwestern.edu
Current Hematology Reports
|July 13, 2005
Summary
High-dose therapy with autologous hematopoietic progenitor cell transplantation (AHPCT) shows promise for pediatric solid tumors like neuroblastoma and Wilms' tumor. However, its effectiveness is limited in certain cancers, such as Ewing's sarcoma, warranting further investigation.
Area of Science:
- Pediatric Oncology
- Hematopoietic Stem Cell Transplantation
Background:
- Solid tumors are a major cause of mortality in children.
- Conventional therapies are insufficient for high-risk pediatric solid tumor patients.
- Dose-intensified myeloablative therapy with autologous hematopoietic progenitor cell transplantation (AHPCT) is being explored to improve outcomes.
Purpose of the Study:
- To evaluate the role of AHPCT in treating various pediatric solid tumors.
- To discuss the current controversies surrounding AHPCT in pediatric oncology.
Main Methods:
- Review of recent studies on AHPCT for pediatric solid tumors.
- Analysis of treatment responses and survival data for different tumor types.
Main Results:
- AHPCT has shown encouraging results in metastatic neuroblastoma and recurrent Wilms' tumor.
- Limited benefit has been observed with AHPCT in Ewing's sarcoma.
- The efficacy of AHPCT varies significantly across different pediatric solid tumors.
Conclusions:
- AHPCT is a promising, albeit not universally effective, treatment modality for select pediatric solid tumors.
- Further research is needed to optimize AHPCT protocols and identify patient subgroups most likely to benefit.
- Ongoing debates regarding AHPCT highlight the need for continued investigation into its role in pediatric cancer therapy.